Benzinga | Nov 22, 2021 09:30AM EST

Credit Suisse Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to $105

Credit Suisse analyst Tiago Fauth maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and raises the price target from $100 to $105.